ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1256

Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
Abstract Number: 1780

Maternal and Fetal Outcomes in Pregnant Women with Psoriatic Arthritis: A Systematic Literature Review
Abstract Number: 1767

Maternal Peripartum Outcomes Are Similar to the General Population in Rheumatoid Arthritis Pregnancies
Abstract Number: 0789

Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Abstract Number: L06

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Abstract Number: 0941

MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria
Abstract Number: 0140

Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis
Abstract Number: 1560

Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry
Abstract Number: 1437

Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener’s) (GPA)
Abstract Number: 1886

Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH
Abstract Number: 1696

Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative
Abstract Number: 0594

Mechanical and Temperature Stress During Biologic Shipments to Rheumatology Patients
Abstract Number: 1658

Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis
Abstract Number: 0373

Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
Abstract Number: 0576

Medical Savings of Timely Rheumatoid Arthritis Diagnoses

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].